Traditional drug development in Alzheimer's disease is taking too narrow an approach by focusing intensively on the buildup of amyloidbeta-protein in the brain, Dr. Nixon says.
传统的治疗老年痴呆症的药物研发思路仅仅集中在淀粉样β蛋白的累积上,Nixon博士说。
2
People with the disease get plaques in their brains made up of a small protein called amyloid-beta, which clumps together and disrupts brain signals.